INTRODUCTION
Breast cancer is the second leading cause of death among women with cancer. Early prediction of the likelihood of treatment response can lead to more effective treatment and reduced mortality.
Currently, assessment of breast cancer treatment response relies on tumor markers, e.g., CA125, tissue biopsy or imaging. [1] [2] [3] [4] [5] [6] However, tumor markers are influenced by other factors, so that they lack sensitivity and specificity, while tissue biopsy is an invasive process associated with sampling errors.
Conventional x-ray mammography has been shown to reduce mortality of breast cancer by about 30% in women older than 50 years of age and by 17% in women ages 40-50. 7,8 Though mammography is relatively inexpensive, it is not sensitive in detecting breast cancer (25-30%) in women with dense breast tissue, 7 and is not useful for early prediction of therapeutic response. Similarly, computed tomography (CT), ultrasound, and chest x-rays are not helpful in predicting therapeutic response. MRI is used to follow-up on treatment changes, providing perfusion and diffusion information, with the status of blood flow. 9 Molecular targets (e.g., estrogen, progestin, folate, retinoic acid receptors, BRCA-1, HER-2/neu, p53, cyclin D1) provide more accurate functional information for breast cancer diagnosis and treatment. [10] [11] [12] [13] [14] [15] [16] [17] Tagging molecular targets with radionuclides can increase our understanding of pharmacokinetic, pharmacodynamic and metabolic imaging patterns of the agent, thereby providing information useful for characterizing tumors.
Apoptosis, programmed cell death, is a natural, orderly, energy-dependent process that causes cells to die without inducing an inflammatory response. 18, 19 Apoptosis is triggered either by a decrease in factors required to maintain the cell in good health or by an increase in factors that cause damage to the cell. 20, 21 When these factors tilt in the direction of death and the cell has sufficient time to respond, a proteolytic cascade involving cysteine aspartic acid-specific proteases (caspases) is activated to initiate apoptosis. 22 Cells that die by apoptosis autodigest their DNA and nuclear proteins, change the phospholipid composition on the outer surface of their cell membrane, and form lipid enclosed vesicles, which contain noxious intracellular contents, organelles, autodigested cytoplasm, and DNA. The compositional cell membrane phospholipid change that occurs with the onset of apoptosis is marked by the expression of phosphatidylserine (PS). PS, a phospholipid that constitutes 10-15% of phospholipid content and appears on the inner leaflet of the membrane, is redistributed onto the external leaflet of the membrane during apoptosis. 23 Annexin V binds to phosphatidylserine during apoptosis, [24] [25] [26] and radiolabeled annexin V may be useful in evaluating the efficacy of therapy and disease progression or regression. Imaging of apoptosis has been achieved by ultrasound, 27 confocal laser scanning microscopy 28 and a fluorescent probe. 29 Fluorescence-labeled annexin V is used for histologic and cell-sorting studies to identify apoptotic cells. Due to the sensitivity, specificity, accessibility, and cost, this technique is not suitable for in vivo imaging studies.
99m Tc-HYNIC-annexin has been shown to be useful in imaging apoptosis in liver transplantation in animal models. [30] [31] [32] However, labeling HYNIC with 99m Tc requires two other chemicals, thiphenylphosphine and tricin, which are inconvenient for the formation of a kit preparation . Among all chelators  for  99m Tc-chemistry, L,L-ethylenedicysteine (EC)  is the most stable and successful example of N 2 S 2  chelates. 33-40 EC-drug conjugates can be labeled with 99m Tc easily and efficiently with high radiochemical purity and stability. Thus, we developed a noninvasive method to detect and measure apoptosis by tagging annexin with 99m Tc-using EC as a chelator. In this paper, synthesis, cellular uptake, biodistribution, breast tumor imaging, and quantification of treatment changes using 99m Tc-EC-annexin V are reported.
MATERIALS AND METHODS

Synthesis of L,L-Ethylenedicysteine (EC)
Mass spectral analyses were conducted at the University of Texas Health Science Center (Houston, TX). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker-300 Spectrometer. The mass data were obtained by fast atom bombardment on a Kratos MS 50 instrument (England). N-hydroxysulfosuccinimide (Sulfo-NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbo-diimide-HCl (EDC) were purchased from Pierce Chemical Co (Radford, IL). All other chemicals were purchased from Aldrich Chemical Co (Milwaukee, WI). Silica gel coated thin-layer chromatography (TLC) plate was purchased from Whatman (Clifton, NJ). EC was prepared in a two-step synthesis according to the previously described methods. 41, 42 The precursor, L-thiazolidine-4-carboxylic acid, was synthesized (m.p. 195°, reported 196-197°). EC was then prepared (m.p. 243°C, reported 251°C).
Synthesis and Radiolabeling of EC-Annexin
Sodium bicarbonate (1N, 1 ml) was added to a stirred solution of EC (5 mg, 0.019 mmol). To this colorless solution, sulfo-NHS (4 mg, 0.019 mmol) and EDC (4 mg, 0.019 mmol) were added. Annexin V (M.W. 33 kD, human, Sigma Chemical Company) (0.3 mg) was then added. The mixture was stirred at room temperature for 24 hrs. The mixture was dialyzed for 48 hrs with cutoff at M.W.10,000. After dialysis, the product was freeze dried, with the product in the salt form weighing 0.5 mg.
99m Tc-pertechnetate was obtained from Syncor Pharmaceutical Inc. (Houston, TX). Radiosynthesis of 99m Tc-EC-annexin was achieved by adding the required amount of 99m Tc-pertechnetate into EC-annexin (50 mg) and tin chloride (II) (SnCl 2 , 100 mg). The mixture was loaded on a sephadex gel column (PD-10, G-25, Pharmacia Biotech, Swiss) and eluted with phosphate buffered saline (pH 7.4). One ml of each fraction was collected. The product was collected at fraction 3, yielding 70%. Radiochemical purity was assessed by Radio-TLC (Bioscan, Washington, DC) using 1M ammonium acetate: methanol (4/1) as an eluant and HPLC. HPLC, equipped with NaI detector and UV detector (254 nm), was performed on a GPC column (Biosep SEC-S3000, 7.8 3 300 mm, Phenomenex, Torrance, CA) using a flow rate of 1.0 ml/min. The eluant was 0.1% LiBr in PBS (10 mM, pH 5 7.4).
In Vitro Cellular Uptake Assay
Paclitaxel-induced apoptosis
Breast tumor cells were obtained from RBA CRL-1747 rat breast cancer cell line (American Type Culture Collection, ATCC, Rockville, MD). This cell line was derived from a tumor induced in Fischer-344 rat by giving an oral dose of 7,12-dimethyl-benz[a]anthracene. The cells were cultured in Eagle's MEM with Earle's BSS (90%) and fetal bovine serum (10%). Breast tumor cells (5.0 3 10 4 cells/0.5 ml buffer/well) were treated with paclitaxel (0-100 ng/20 ml/well). After 24 hrs incubation, cell viability was determined by methylene tetrazolium (MTT) assay.
43 99m Tc-EC-annexin (2 mCi/well, 1.5 mg/well) was added to the cells. After 2 and 4 hrs incubation, the cells were washed twice with ice cold PBS (1 ml), and trypsin EDTA (0.1 ml) was added. After 2 min, PBS (0.4 ml) was added and the total volume containing cells was transferred to a test tube to count the activity. 99m Tc-pertechnetate was used as a control. Each data represents an average of four measurements, that were calculated as percentage of uptake per number of viable cells.
Radiation-induced apoptosis
To quantify cellular uptake during the apoptotic process using 99m Tc-EC-annexin V, breast tumor cells (2.5 3 10 5 cell/5 ml buffer/well) were irradiated with a Cs-137 external beam source (0-30 Gy/well). After three-day incubation, cell viability was determined by MTT assay.
99m Tc-EC-annexin (10 mCi/well, 7.5ìg/well) was added to the cells. After 2 hrs incubation, the cells were washed twice with ice cold PBS (1 ml), after which trypsin EDTA (0.5 ml) was added. After 2 min, PBS (2 ml) was added. Unbound 99m Tc-EC-annexin was removed by centrifugation and the total volume containing the cells was transferred to a test tube to count the activity. Each data represents an average of three measurements, that were calculated as percentage of uptake per number of viable cells. Apoptotic cells were simultaneously quantified by fluorescence microscopic enumeration of apoptotic cells using Hoechst 33342 staining (Fisher Scientific, Houston, TX). The Hoechst 33342 morphological analysis was chosen as a nondestructive method in which the classic morphology of early, late apoptotic cells and early membrane permeability changes can be evaluated on intact cells. 44 Briefly, fresh cells were stained with Hoechst 33342 at 0.1 mg/ml in complete medium for 15 min at 37°C. Cell morphology was examined using an inverted fluorescence microscope (Wetzlar, Leica, Germany).
Tissue Distribution Studies
Female Fischer 344 rats (150-25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were inoculated subcutaneously with 0.1 ml of mammary tumor cells from the RBA CRL-1747 rat breast cancer cell line (10 6 cells/rat) into the hind legs. Studies were performed 14 to 17 days after implantation when tumors reached approximately 1 cm in diameter.
In tissue distribution studies, each animal was injected intravenously (i.v.) with 99m Tc-EC-annexin or 99m Tc-EC (10 mCi/rat, n 5 3 rats/time point) through tail vein. The injected mass of each ligand was 10 mg per rat. At 30 min, 2 and 4 hrs following administration of the radiotracers, the animals were sacrificed and the tumor and selected tissues were excised, weighed and counted for radioactivity by using a gamma counter (Packard Instruments, Downers Grove, IL). The biodistribution of tracer in each sample was calculated as percentage of the injected dose per gram of tissue wet weight (%ID/g). Student-t test was used to assess the significance of differences between two groups.
Scintigraphic Imaging Studies
Scintigraphic images, using a gamma camera (Siemens Medical Systems, Inc., Hoffman Es-
To ascertain the tumor treatment response, the same pre-imaged rats were administered paclitaxel (40 mg/kg, iv tail vein, day 14) and images were taken on days 16 and 18. Computer outlined regions of interest (ROI) (counts per pixel) were used to determine tumor-to-background count density ratios. The ratios were used to compare dynamic tumor uptake pre-and post-treatment. Errors in the use of image ROIs as standards to correspond to anatomically relevant features have been described and found tolerable. 45, 46 
RESULTS
Chemistry
EC was conjugated to amino or lysine residue of annexin V. A simple and efficient synthesis of 99m Tc-EC-annexin was developed.
99m Tc-EC-annexin was found to be radiochemically pure (100%). The retention time of 99m Tc-EC-annexin was at 9.63 min (Figure 1 ). Under the same condition, the retention time of 99m Tc-EC (control) was at 14.03 min (data not shown). The amount injected to HPLC was 3 mCi per 22.5 ng of 99m Tc-EC-annexin. The specific activity was calculated to be 5 Ci/mmol.
In Vitro Cellular Uptake Assay
Paclitaxel-induced apoptosis
There was a markedly increased uptake of 99m Tc-EC-annexin V in the paclitaxel (100 ng/well) treated group compared to non-treated groups at 2 and 4 hours incubation (Figure 2 ). Similar findings in the paclitaxel (50 ng/well) treated group at 4 hours incubation were observed. This increased uptake is likely due to apoptotic bodies formed in the cells which correlates with the appearance of apoptotic bodies shown in Figures 3  and 4 . Apoptotic cells were brightly stained and the classic progression of chromatin condensation and nuclear fragmentation was visible. The in vitro findings indicated that 99m Tc-EC-annexin V is useful in measuring apoptotic processes before and after paclitaxel treatment.
Radiation-induced apoptosis
Significantly increased uptake of 99m Tc-EC-annexin V was observed in radiation-treated groups (10 and 30 Gy) compared to non-treated groups at 2 hours incubation ( Figure 5 ).
In Vivo Biodistribution and Scintigraphic Imaging Studies
In biodistribution studies, unlike 99m Tc-EC groups (Table 1) , tumor-to-tissue count density ratios in 99m Tc-EC-annexin groups showed an increased uptake as a function of time (Table 2) . Tumor uptake (%ID/G) in 99m Tc-EC-annexin groups was higher than 99m Tc-EC. Liver uptake in 99m Tc-EC-annexin groups was also higher than 99m Tc-EC groups. The difference in liver uptake may be due to their different molecular weights (M.W. 35,000 of annexin vs 268 of EC). Although high uptake in kidneys was observed in 99m Tc-EC and 99m Tc-EC-annexin groups, this may be due to the route of excretion of both agents.
Scintigraphic images of 99m Tc-EC-annexin 4 cells/well) was selected for this study. Cell culture was performed in 24-well plate. After adding paclitaxel (0-100 ng/well), followed by 24 hrs incubation, 99m Tc-EC-annexin V (2mCi) was added to each well and incubated for 2-4 hours. Each bar represents an average of four measurements. Viable cells were determined by methylene tetrazolium (MTT) assay. Each data was calculated as percentage of uptake per number of viable cells. There was a markedly increased uptake of 99m Tc-EC-annexin V in paclitaxel treated groups (50 and 100 ng) compared to non-treated groups at 4 hrs incubation. An asterisk indicates significant (p , 0.05) difference between treated and untreated groups at the same time interval. demonstrated that these relatively large tumors could be visualized well on day 14 after inoculation of tumor cells ( Figure 6 ). However, there was a significantly increased uptake (ROI ratios) of 99m Tc-EC-annexin in tumors after paclitaxel treatment when compared to pretreatment uptake. Differences were observed in ROI ratios between pre-and post-treatment on day 5 post-treatment at 2 hrs and on day 3 post-treatment at 1, 2 and 4 hrs (Table 3) .
DISCUSSION
Improvement of scintigraphic tumor diagnosis, prognosis, planning, and monitoring of treatment of cancer will clearly be determined by the development of more tumor-specific radiopharmaceuticals. Radionuclide imaging modalities (positron emission tomography, PET; single photon emission computed tomography, SPECT) are diagnostic cross-sectional imaging techniques 5 cell/5 ml buffer/well) were irradiated with a Cs-137 external beam source (0-30 Gy/well). After three-day incubation, cell viability was determined by MTT assay. 99m Tc-EC-annexin (10mCi/well, 7.5mg/well) was added to the cells. Unbound 99m Tc-EC-annexin was removed by centrifugation and the total volume containing cells was transferred to a test tube to count the activity. Significantly increased uptake of 99m Tc-EC-annexin V was observed in radiation-treated groups (10 and 30 Gy) compared to non-treated groups at 2 hrs incubation. Each data represents an average of three measurements, that were calculated as percentage of uptake per number of viable cells.
that map the location and concentration of radionuclide-labeled radiotracers. Although CT and MRI provide considerable anatomic information about the location and the extent of tumors, these imaging modalities cannot adequately differentiate invasive lesions from edema, radiation necrosis, or gliosis. [47] [48] [49] [50] [51] PET and SPECT have been used to localize and characterize tumors by measuring functional and metabolic activities.
To characterize tumors, radiolabeled ligands, radiolabeled antibodies, and signal transduction agents have opened a new era and have undergone extensive preclinical development and evaluation. 52, 53 The strategy of labeling biomolecules for molecular imaging has generated considerable interest, but focus must first be on the stability and efficient attachment of isotopes. Several 99m Tc-labeling techniques have been reported, and they include N 4 (e.g. DOTA), N 3 S (e.g., MAG-3), N 2 S 2 (e.g., ECD), NS 3 , S 4 (e.g., Values shown represent the mean 6 standard deviation of data from 3 animals. sulfur colloid), DTPA, and HYNIC. [30] [31] [32] 37, [54] [55] [56] Among these chelators, the DTPA moiety does not chelate with 99m Tc as stably as with 111 In. 56 The HYNIC technique requires two additional chemicals (tricine, triphenylphosphine) in order to form a Tc-99m complex, thus making it inconvenient to formulate in a kit form and costly. The nitrogen and sulfur combination has been shown to be a stable chelator for 99m Tc. Bisaminoethanethiol tetradentate ligands, also called diaminodithiol compounds, are known to form very stable Tc(V)O-complexes on the basis of efficient binding of the oxotechnetium group to two thiolsulfur and two amine nitrogen atoms.
99m Tcethylenedicysteine ( 99m Tc-EC) is a successful example of N 2 S 2 chelates. Using a standard coupling technique, 99m Tc-EC-drug conjugates were then developed to characterize tumor tissues. 57, 58 In vivo biodistribution and planar imaging studies in tumor-bearing rats given 99m Tc-EC-annexin V demonstrated the pharmacokinetic distribution of the tracer and feasibility of using this molecular marker to image tumors. Tumor-to-tissue count density ratios were increased as a function of time suggesting that 99m Tc-EC-annexin V is a tumor specific marker.
Apoptosis occurs during the treatment of cancer with chemotherapy and radiation. Apoptosis can be induced by antibiotics, radiation, Fas-mediated antibody, and anticancer drugs. 25, 26, [59] [60] [61] [62] Apoptosis can occur early, therefore both tumor volume and tumor uptake of annexin need to be measured. Annexin V is known to bind to phosphatidylserine, which is overexpressed by tumor apoptotic cells. Assessment of apoptosis by annexin V could be useful to evaluate the efficacy of therapy and disease progression or regression. Decreased tumor volume, increased uptake of annexin at an early time, and later decreased uptake after treatment would reflect a positive treatment response.
The timing of apoptosis may have occurred at earlier time interval as evidenced by increased ROI ratios at 2 hrs on day 3 post-treatment. However, at day 18 (day 5 post-treatment), both apoptosis and necrosis may have occurred and that may account for tumor response. To demonstrate cellular distribution of 99m Tc-EC-annexin V with and without paclitaxel or radiation treatment, microautoradiographic technique would provide detailed information on the distribution of 99m Tc-EC-annexin V in a whole intact cell from the membrane to the nucleus.
In summary, a simple labeling method for Figure 6 . Planar images of breast tumor-bearing rats following administration of 99m Tc-EC-annexin V (100 mCi/rat, iv.) showed that tumor uptake could be visualized from 5 min to 4 hrs on day 14 after inoculation of tumor cells. preparation of high specific activity 99m Tc-ECannexin was developed. In vitro cell culture revealed that there was significantly increased cellular uptake of 99m Tc-EC-annexin after irradiation or paclitaxel treatment. This increased uptake was likely due to the formation of apoptotic bodies as shown by Hoechst staining. In vivo imaging studies showed that there were transiently increased tumor/non-tumor ratios after paclitaxel treatment. In vitro and in vivo findings indicate that 99m Tc-EC-annexin, a marker for apoptosis, may be useful in assessing the outcome of cancer treatment.
